Advertisement

Topics

FDA approves Dynavax’s HEPLISAV-B for adult hepatitis B prevention

09:57 EST 10 Nov 2017 | CentreWatch

Dynavax Technologies announced that the FDA has approved HEPLISAV-B [Hepatitis B Vaccine, Recombinant (Adjuvanted)] for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older. HEPLISAV-B is the first new hepatitis B vaccine in the U.S. in more than 25 years and the only two-dose hepatitis […]

The post FDA approves Dynavax’s HEPLISAV-B for adult hepatitis B prevention appeared first on CenterWatch News Online.

Original Article: FDA approves Dynavax’s HEPLISAV-B for adult hepatitis B prevention

NEXT ARTICLE

More From BioPortfolio on "FDA approves Dynavax’s HEPLISAV-B for adult hepatitis B prevention"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...